
Leukemia cancer cells before and after new drug treatment.
CREDIT
Waleed Minzel/Hebrew University.
Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
Learn more:Â For first time in 40 years, cure for acute leukemia within reach
The Latest on: Acute myeloid leukemia
[google_news title=”” keyword=”acute myeloid leukemia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Acute myeloid leukemia
- Floydada 6-year-old inspires family to keep going as he battles second round of leukemiaon February 8, 2023 at 8:27 pm
A Floydada kindergartner is staying strong as he faces his second battle with leukemia and is inspiring his family to keep fighting.
- Floydada community gives back to 2 of its studentson February 8, 2023 at 7:20 pm
Hunter Wells and Toby Zepeda – have battled with separate medical issues and the Floydada community lent a helping hand Tuesday night. The district donated proceeds from admission to Tuesday’s games ...
- Acute Myeloid Leukemia Market Size in 2023 is Dominating [ Medical Care Sector ] till 2028on February 8, 2023 at 8:28 am
Feb 08, 2023 (The Expresswire) -- ""Acute Myeloid Leukemia Market"" Research report Insights 2023 | TOP 3 COMPANIES Operating in Acute Myeloid ...
- 2023 Acute Myeloid Leukemia (AML) Biomarker Testing Market: Top Growing Regions and Competitors Analysis by 2028on February 8, 2023 at 12:32 am
Modern Research - ” Forecast by Growth, Size and Share 2023-2028 Acute Myeloid Leukemia (AML) Biomarker Testing Market Research Report focuses on industry segments with types, applications and regions ...
- Novel type of combination therapy shows potential in acute myeloid leukemiaon February 7, 2023 at 6:51 pm
Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood and can quickly cause death if not treated promptly.
- Drug combination shows potential in aggressive leukemiaon February 7, 2023 at 11:58 am
Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood, and can quickly cause death if not treated promptly. Despite recent ...
- Characterization of Ikaros zinc finger protein 1 mutations in acute myeloid leukemiaon February 2, 2023 at 3:58 am
Researchers evaluated the clinical and genetic characteristics of acute myeloid leukemia (AML) patients with a mutant Ikaros zinc finger protein 1 (IKZF1).
- Bone Marrow or Stem Cell Transplants for Acute Myeloid Leukemia (AML)on February 1, 2023 at 9:25 am
A bone marrow or stem cell transplant may be beneficial for people with intermediate- to high-risk acute myeloid leukemia (AML) who are in remission and can tolerate an intensive treatment plan.
- Acute Myeloid Leukemia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 200+ Companies Working in the Domainon January 30, 2023 at 7:30 am
DelveInsight's 'Acute Myeloid Leukemia Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, ...
- Acute myelogenous leukemia / ONCOLOGY NHBAon January 29, 2023 at 1:48 pm
Acute myelogenous leukemia is also known as acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. Symptoms General signs and symptoms ...
via Bing News